Woman Man
- | Country : -
- | organs : -
- | Specialty : -
Extract
The primary objective of this study is to demonstrate comparable clinical efficacy of SB3 to Herceptin®, in terms of Pathologic complete response rate of the primary breast tumour in women with HER2 positive Early breast cancer or Locally advanced breast cancer in neoadjuvant setting.
Inclusion criteria
- newly diagnosed primary HER2 positive early or locally advanced breast cancer